β3-Adrenoceptor agonists: potential, pitfalls and progress
Introduction
Although the β3-adrenoceptor was not cloned until 1989 (Emorine et al., 1989), it had already been apparent for 5 or 6 years that agonists of this receptor might have potential in the treatment of obesity and Type 2 diabetes Arch and Ainsworth, 1983, Arch et al., 1984a. Early evidence for the β3-adrenoceptor stemmed from the discovery that β1- and β2-adrenoceptor antagonists lacked potency in various gut preparations and as antagonists of β-adrenoceptor agonist-driven lipolysis. Then in the early 1980s, novel β-adrenoceptor agonists were discovered to be more potent as stimulants of rat white or brown adipocyte lipolysis than as stimulants of atrial contraction, or tracheal or uterine relaxation (Arch et al., 1984a). These compounds were found to stimulate metabolic rate and to have anti-obesity and anti-diabetic (insulin-sensitising) activity in rats and mice Arch et al., 1984b, Meier et al., 1984, Yen et al., 1984, Cawthorne et al., 1984.
Since that time, numerous studies have produced similar results in rodents for other β3-adrenoceptor agonists (e.g. Umekawa et al., 1997, Kiso et al., 1999); the β3-adrenoceptor and β3-adrenoceptor agonists have been reviewed regularly Arch and Kaumann, 1993, Arch, 2001, Dow, 1997, Weyer and de Souza, 2000, and there have been two books on the subject Goldberg and Frishman, 1995, Strosberg, 2000. No β3-adrenoceptor agonist has, however, advanced beyond Phase II clinical studies. In this brief review, I shall describe the status and discuss the potential of β3-adrenoceptor agonists for the treatment of obesity, touching also upon Type 2 diabetes. First though, I shall describe some of the problems of identifying β3-adrenoceptor agonists suitable for development as drugs.
Section snippets
Rodent vs. human receptors
The first generation β3-adrenoceptor agonists were identified largely from studies in vivo in rats and mice. These compounds were therefore optimised for selectivity at the rodent β3-adrenoceptor. When the human β3-adrenoceptor was cloned and expressed by Strosberg et al. (Emorine et al., 1989), one of the first generation compounds [(RR+SS)-(±)-4-[2-(2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl]phenoxyacetate (BRL-37344)] was shown to be a potent stimulant of cyclic AMP synthesis. It was
Role of the β3-adrenoceptor in man
The key sites of action for β3-adrenoceptor agonists appear to be skeletal muscle (Astrup et al., 1985), brown adipose tissue (Foster and Frydman, 1978) and (not as a site of thermogenesis but as a source of fuel) white adipose tissue Schiffelers et al., 1998, Havel et al., 1964. For a fuller discussion, see Arch (2001). β3-adrenoceptor mRNA is expressed in lower amounts in human than in rodent adipose tissue and the promoter for the human β3-adrenoceptor appears to drive expression of the mRNA
Status report
The attraction of β3-adrenoceptor agonists as potential drugs for the treatment of obesity and Type 2 diabetes is plain to see. The difficulties of producing a compound with good efficacy, selectivity and pharmacokinetic properties suitable for stimulation of the small numbers of β3-adrenoceptor present in man have, however, defeated a number of pharmaceutical companies. Recent interest has been evident from Merck, from where there have been a number of publications, but an abstract describing
Acknowledgments
I am grateful to Elliot Danforth Jr. and Terry Kenakin for the suggestions that have improved this manuscript, and to David G. Smith for the chemical advice. I would also like to thank Rosemary Wallis for the many manuscripts that she has prepared for me on β3-adrenoceptors and other topics during my time at SmithKline Beecham and GlaxoSmithKline.
References (78)
- et al.
Anti-obesity drugs: a critical review of current therapies and future opportunities
Pharmacol. Ther.
(2001) Four β-adrenoceptor subtypes in the mammalian heart
Trends Pharmacol. Sci.
(1997)- et al.
Inhibition of lipolysis reduces β1 adrenoceptor-mediated thermogenesis in man
Metabolism
(1998) - et al.
The effect of a novel β-agonist BRL 26830A on weight and protein loss in obese patients
Int. J. Obes.
(1987) - et al.
Meta-analysis of the association of the Trp64Arg polymorphism in the β3-adrenergic receptor with body mass index
Int. J. Obes.
(1998) β3-Adrenoceptor ligands and pharmacology of the β3-adrenceptor
The β3-adrenergic system and β3-adrenergic agonists
Rev. Endocr. Metab. Dis.
(2001)- et al.
Reduction of obesity in mice with a novel type of thermogenic β-adrenergic agonist
Int. J. Obes.
(1983) - et al.
β3 and atypical β-adrenoceptors
Med. Res. Rev.
(1993) - et al.
Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs
Nature
(1984)
Treatment of obesity with thermogenic β-adrenoceptor agonists: studies on BRL 26830A in rodents
Int. J. Obes.
Influences on body composition and mechanism of action of the β-adrenoceptor agonist BRL 26830A
Studies on a novel selective β3-adrenoceptor agonist in human right atrial appendage and human white adipocytes
Br. J. Pharmacol.
Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man
Am. J. Physiol.
Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice
Horm. Metab. Res.
Potent and selective human β3-adrenergic receptor antagonists
J. Pharmacol. Exp. Ther.
Effects of novel β-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin dependent diabetes
Int. J. Obes.
BRL 35135, a potent and selective atypical β-adrenoceptor agonist
Am. J. Clin. Nutr.
The tissue distribution of the human β3-adrenoceptor studies using a monoclonal antibody
Int. J. Obes.
The effects of a new β-adrenoceptor agonist BRL 26830A in refractory obesity
Int. J. Obes.
Binding, gating and efficacy
Br. J. Pharmacol.
Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical β adrenoceptor agonist
Br. Med. J.
β3-Adrenergic agonists: potential therapeutics for obesity
Expert Opin. Invest. Drugs
Factors influencing the composition of the weight lost by obese patients on a reducing diet
Br. J. Nutr.
Molecular characterisation of the human β3-adrenergic receptor
Science
A selective human β3 adrenergic receptor agonist increases metabolic rate in Rhesus monkeys
J. Clin. Invest.
Nonshivering thermogenesis in the rat: II. Measurements of blood flow with microspheres point to brown adipose tissue as the dominant site of the calorigenesis induced by noradrenaline
Can. J. Physiol. Pharmacol.
Meta-analysis of the association of Trp(64)Arg polymorphism of β3-adrenergic receptor gene with body mass index
J. Clin. Endocrinol. Metab.
Lipolytic effects of conventional β3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells : preliminary pharmacological evidence for a putative β4-adrenoceptor
Br. J. Pharmacol.
The negative inotropic action of catecholamines: role of β3-adrenoceptors
Can. J. Physiol. Pharmacol.
β3-Adrenergic Agonism
Primates in the experimental pharmacology of obesity
Studies on the relation between mobilization of free fatty acids and energy metabolism in man: effects of norepinephrine and nicotinic acid
Metabolism
Effects of several putative β3-adrenoceptor agonists on lipolysis in human omental adipocytes
Int. J. Obes.
Polymorphism of the human β3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function
Diabetes
Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes
Diabetologia
Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle
Br. J. Pharmacol.
Mice expressing human but not murine β-adrenergic receptors under the control of human gene regulatory elements
Diabetes
Anti-diabetic and anti-obesity effects of AJ-9677, a novel human β3-adrenoceptor agonist, in genetically obese diabetic mice
Jpn. J. Pharmacol.
Cited by (201)
Theoretical insights on the interaction between p-synephrine and Metformin: A DFT, QTAIM and Drug-Likeness investigation
2024, Computational and Theoretical ChemistrySelf-reporting molecularly imprinted polymer with the covalently immobilized ferrocene redox probe for selective electrochemical sensing of p-synephrine
2021, Sensors and Actuators, B: ChemicalInduction of UCP1 and thermogenesis by a small molecule via AKAP1/PKA modulation
2020, Journal of Biological ChemistryRegulation of thermogenic adipocytes during fasting and cold
2020, Molecular and Cellular Endocrinology